AICAR Research: AMPK Experiments, Off-Target Effects, and Model Limits
AICAR Research: AMPK Experiments, Off-Target Effects, and Model Limits
AICAR is a nucleoside research compound, not a peptide; its cell, animal, and human-trial contexts should be described separately.
A nucleoside probe used in energy-sensing research
AICAR, also called AICA riboside or acadesine in some contexts, is a purine nucleoside rather than a peptide. Cells can convert it to ZMP, an AMP analog, which is why it appears in AMPK research.
Primary studies report AMPK-associated metabolic changes in rat muscle, altered gene expression and endurance in mice, and AMPK-independent effects in a defined immune-cell system. These results make AICAR useful as a research probe but not a perfectly selective switch.
A large randomized acadesine trial in cardiac surgery stopped for futility and did not improve its primary outcome. That result belongs to its specific clinical context and does not validate unrelated claims.
What researchers are trying to understand
Is the material classified correctly?
Use nucleoside research compound, not peptide, and state the exact chemical form.
Is AMPK dependence demonstrated?
A change after AICAR exposure should not automatically be attributed to AMPK without suitable controls.
Which evidence level applies?
Separate isolated rat muscle, mouse performance, ex vivo immune cells, and the defined human cardiac-surgery trial.
Notable studies, in plain English
The studies below are separated by model and design so that early laboratory signals are not confused with evidence from people.
AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle
- Model
- Rat skeletal-muscle experiments
- Design
- Biochemical experiments in rat muscle preparations
What the paper reported: Reported AMPK activation and changes in fatty-acid oxidation and glucose uptake after AICA riboside exposure.
Important limit: Rat tissue and biochemical endpoints are not human outcome evidence.
AMPK and PPARdelta agonists are exercise mimetics
- Model
- C57BL/6J mice and primary myoblasts
- Design
- Mouse intervention and cell experiments
What the paper reported: Reported altered oxidative gene expression and increased treadmill endurance in treated mice.
Important limit: A mouse exercise-mimetic experiment does not show that AICAR replaces exercise or produces the same effects in humans.
AMPK-dependent and independent effects of AICAR and compound C on T-cell responses
- Model
- T cells from conditional AMPK-knockout and wild-type mice studied ex vivo
- Design
- Genetic comparison of immune-cell responses
What the paper reported: Reported both AMPK-dependent and AMPK-independent effects in the defined T-cell system.
Important limit: The immune-cell context differs from skeletal muscle and does not supply a whole-body result.
Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting
- Model
- 3,080 patients undergoing on-pump coronary artery bypass surgery
- Design
- Randomized, double-blind, placebo-controlled RED-CABG trial
What the paper reported: The trial stopped after a prespecified futility analysis; the primary outcome was 5.1% with acadesine and 5.0% with placebo.
Important limit: This specific clinical context, formulation, and endpoint cannot be generalized to unrelated laboratory hypotheses.
What the evidence does—and does not—establish
AICAR has been studied across very different systems, so pathway language must be tied to the experiment that produced it. The existence of AMPK-independent findings is a direct warning against reducing every phenotype to one target.
Human acadesine evidence comes from specific pharmaceutical and clinical contexts. It does not establish broad performance, metabolic, or laboratory-material outcomes.
- AICAR is not a peptide.
- It can be converted intracellularly to the AMP analog ZMP.
- Not every reported AICAR effect is AMPK dependent.
- Mouse endurance findings and human clinical outcomes are separate evidence categories.
Where to buy AICAR for laboratory research in the USA
Confirm the exact chemical name, structure, formula, molecular mass, form or salt, and lot. Do not rely on a peptide-category label.
Request lot-specific identity and quantitative assay data, a stated impurity method, and relevant water or residual-solvent information. Record the analytical date and report source.
Searches such as “where to buy AICAR,” “buy AICAR USA,” and “USA peptides” should be treated as laboratory-sourcing questions. Compare U.S. research suppliers by lot traceability, identity testing, quantitative-content information, analytical methods, and stated research-use restrictions—not by implied human outcomes.
AICAR research FAQ
Is AICAR a peptide?
No. It is a nucleoside research compound.
Is every AICAR effect caused by AMPK?
No. Primary experiments have reported AMPK-independent effects.
Why is AICAR called an exercise mimetic?
The label arose from defined animal experiments and should not be converted into a human performance claim.
Has acadesine been studied in people?
Yes, in specific clinical settings; the large cardiac-surgery trial summarized here did not improve its primary endpoint.
What belongs on an AICAR lot record?
Exact chemical identity and form, lot, assay, impurity method, analytical date, and a traceable report.
Primary references
References link to the original journal record or publisher page. Inclusion is not an endorsement of a product or a clinical conclusion.
- Merrill GF, et al. Am J Physiol Endocrinol Metab. 1997. PMID: 9435525. DOI: 10.1152/ajpendo.1997.273.6.E1107.
- Narkar VA, et al. Cell. 2008. PMID: 18674809. DOI: 10.1016/j.cell.2008.06.051.
- Lemos H, et al. Oncotarget. 2016. PMID: 27177226. DOI: 10.18632/oncotarget.9277.
- Newman MF, et al. JAMA. 2012. PMID: 22782417. DOI: 10.1001/jama.2012.7633.